TNFRSF8 and anaplastic large cell lymphoma: More specific immunotherapies targeting ALCL surface markers or ALK include anti-CD30 chimeric antigen receptor (CAR) T cells, vaccination strategies against ALK, and possible ALK-specific T cell therapies.